XML 49 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Business Combinations (Details Narrative)
$ / shares in Units, € in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Apr. 15, 2021
USD ($)
$ / shares
shares
Apr. 15, 2021
USD ($)
$ / shares
Feb. 24, 2021
USD ($)
shares
Jun. 30, 2020
USD ($)
Jan. 31, 2020
USD ($)
d
shares
Sep. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
Apr. 15, 2021
EUR (€)
Feb. 02, 2021
USD ($)
Dec. 31, 2020
USD ($)
Business Acquisition [Line Items]                          
Shares issued, amount           $ 6,241,000 $ 77,987,000 $ 18,343,000          
Operating lease, right use of asset [1]           3,499,000 3,499,000           $ 3,397,000
Fair value of contingent consideration             2,300,000            
Common stock value           251,238,000 251,238,000           157,160,000
Equity Method Investments                     13,417,000
Business combination assumed liabilities $ 40,865,000 $ 40,865,000     $ 13,943,000                
Amount of liabilities           68,992,000 68,992,000           21,936,000
Deferred Revenue           500,000 500,000            
Goodwill $ 9,238,000 $ 9,238,000     9,187,000 18,432,000 18,432,000           9,187,000
Razor Genomics, Inc. [Member]                          
Business Acquisition [Line Items]                          
Shares issued, amount     $ 5,700,000                    
Stock issued during the period | shares     982,318                    
Deferred tax liability     $ 7,564,000                    
Equity ownership percentage     25.00%           25.00%        
Stock purchase price                 $ 10,000,000        
Common stock value     $ 5,756,000                    
Cash paid to purchase shares of common stock     10,000,000                    
Equity Method Investments     13,147,000           $ 11,245,000        
Series A Convertible Preferred Stock [Member] | Razor Genomics, Inc. [Member]                          
Business Acquisition [Line Items]                          
Number of shares purchased | shares                 1,329,870        
Preferred stock, par value | $ / shares                 $ 0.0001        
Milestone Contingent Consideration [Member]                          
Business Acquisition [Line Items]                          
Payments for milestones         $ 6,000,000.0   0            
Discount rate 8.00% 8.00%     7.50%           8.00%    
Credit and risk-adjusted discount rate   21.00%     45.00%                
Cash Holdback [Member]                          
Business Acquisition [Line Items]                          
Cash         $ 600,000               6,400,000
Shares issued, amount         $ 600,000                
Stock Holdback [Member]                          
Business Acquisition [Line Items]                          
Stock issued during the period | shares         200,000                
Stock Holdback One [Member]                          
Business Acquisition [Line Items]                          
Stock issued during the period | shares         1,900,000                
Clinical Trial and Data Publication Milestone [Member] | Milestone Contingent Consideration [Member]                          
Business Acquisition [Line Items]                          
Payments for milestones         $ 1,500,000                
CMS Specified Lung Cancer [Member] | Milestone Contingent Consideration [Member]                          
Business Acquisition [Line Items]                          
Payments for milestones         3,000,000.0                
CMS Reimbursement Milestones [Member] | Milestone Contingent Consideration [Member]                          
Business Acquisition [Line Items]                          
Payments for milestones         1,500,000                
Chronix Biomedica lInc [Member]                          
Business Acquisition [Line Items]                          
Fair value of intangible asset $ 46,800,000 $ 46,800,000                      
Discount rate 12.00% 12.00%                 12.00%    
Deferred tax liability     1,800,000                    
Transaction costs $ 681,000 $ 681,000                      
Goodwill 9,200,000 9,200,000       9,238,000 [2] 9,238,000 [2]           [2]
Chronix Merger Agreement [Member]                          
Business Acquisition [Line Items]                          
Business combination consideration transferred           5,800,000              
Goodwill           5,800,000 5,800,000            
Insight Merger Agreements [Member]                          
Business Acquisition [Line Items]                          
Cash         7,000,000                
Shares issued, amount         5,000,000                
Merger consideration         11,400,000                
Fair value of intangible asset         $ 14,700,000                
Discount rate         35.00%                
Finite-Lived Intangible Assets, Remaining Amortization Period         5 years                
Operating lease, right of use liability         $ 500,000                
Operating lease, right use of asset         $ 100,000                
Merger Agreements [Member]                          
Business Acquisition [Line Items]                          
Trading days | d         5                
Acquisition of offsetting   1,800,000     $ 1,300,000                
Deferred tax liability         $ 1,300,000                
Minority Purchase Agreements [Member]                          
Business Acquisition [Line Items]                          
Common stock value                   $ 10,000,000      
Purchase Agreement [Member]                          
Business Acquisition [Line Items]                          
Common stock value                   $ 5,000,000      
Development Agreement [Member] | Maximum [Member]                          
Business Acquisition [Line Items]                          
Estimated clinical trial expense             16,000,000            
Development Agreement [Member] | Razor Genomics, Inc. [Member]                          
Business Acquisition [Line Items]                          
Clinical trial expense reserve amount     $ 3,400,000     4,000,000 4,000,000            
Development Agreement [Member] | Razor Genomics, Inc. [Member] | CMS Final [Member]                          
Business Acquisition [Line Items]                          
Milestone payment       $ 4,000,000                  
Development Agreement [Member] | Razor Genomics, Inc. [Member] | CMS Final [Member] | Determa Rx [Member]                          
Business Acquisition [Line Items]                          
Property, Plant and Equipment, Estimated Useful Lives       10-year                  
Development Agreement [Member] | Encore Clinical, Inc. [Member]                          
Business Acquisition [Line Items]                          
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross             3,000,000            
Development Agreement [Member] | Encore Clinical, Inc. [Member] | Minority Shareholders [Member]                          
Business Acquisition [Line Items]                          
Shares issued, amount             $ 3,000,000            
Equity method investment, description             If the issuance of shares of common stock having a market value of $3 million            
Laboratory Agreement [Member]                          
Business Acquisition [Line Items]                          
Payment obligation amount           450,000 $ 450,000            
Lease Expiration Date             Sep. 29, 2021            
Chronix Merger Agreement [Member]                          
Business Acquisition [Line Items]                          
Shares issued, amount $ 1,430,000                        
Stock issued during the period | shares 648,000                        
Merger consideration $ 4,000,000.0 4,000,000.0                      
Business combination assumed liabilities $ 1,870,000 $ 1,870,000       $ 5,800,000 $ 5,800,000            
Closing price per share | $ / shares $ 5.09 $ 5.09                      
Business combination settlement net $ 550,000 $ 550,000                      
Merger Agreement [Member] | Chronix Biomedica lInc [Member]                          
Business Acquisition [Line Items]                          
Amount of liabilities $ 4,600,000 4,600,000                   $ 8,250,000  
Value added tax term of contract 3 years 6 months                        
Merger Agreement [Member] | Chronix Biomedica lInc [Member] | German Customer [Member]                          
Business Acquisition [Line Items]                          
Upfront payment received | €                     € 3.7    
Deferred Revenue $ 738,000 738,000                      
Merger Agreement [Member] | Chronix Biomedica lInc [Member] | Maximum [Member]                          
Business Acquisition [Line Items]                          
Business combination consideration transferred   $ 14,000,000                      
Earnout percentage on collections for sales   15.00%                      
Earnout percentage on collections for sale or license   75.00%                      
Merger Agreement [Member] | Chronix Biomedica lInc [Member]                          
Business Acquisition [Line Items]                          
Discount rate 12.00% 12.00%                 12.00%    
[1] Oncocyte recorded certain right-of-use assets and liabilities for operating leases in accordance with ASC 842 (see Notes 3 and 10).
[2] Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in the Insight Merger and the Chronix Merger (see Note 3).